Navigation Links
Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
Date:7/31/2013

thin its supply chain; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems and regulatory reforms, and the continued consolidation of the distribution network through which Warner Chilcott sells its products; changes in tax laws or interpretations that could increase Warner Chilcott's consolidated tax liabilities; government regulation, including U.S. and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including Warner Chilcott's ability and the ability of companies with whom it does business to obtain necessary regulatory approvals; adverse outcomes in Warner Chilcott's outstanding litigation, regulatory investigations or arbitration matters or an increase in the number of such matters to which it is subject; the loss of key senior management or scientific staff; Warner Chilcott's ability to manage the growth of its business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; Warner Chilcott's ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of its existing products; and the other risks identified in Warner Chilcott's periodic filings, including its Annual Report on Form 10-K for the year ended December 31, 2012 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2013 and June 30, 2013, and from time-to-time in its other investor communications.  Warner Chilcott cautions you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in Warner Chilcott's forward-looking statements may not occur. Warner Chilcott undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, excep
'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
10. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
11. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014   Ventana Medical ...  Group, today announced that its VENTANA System for ... in the European Union for routine pathology, including ... consisting of VENTANA Virtuoso software coupled with either ... HT slide scanner, provides automated digital slide creation, ...
(Date:8/20/2014)... Mass. , Aug. 20, 2014 /PRNewswire/ ... electrophysiology (EP) mapping and ablation device market ... use ablation to treat atrial fibrillation (AF). ... primary treatment option for AF will spur ... this application, such as advanced loop diagnostic ...
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. ... Co. Ltd., has received Chinese FDA (CFDA) approval ... mg Tablets into the China ... marketing and distribution agreement with Sinochem Jiangsu Pharmaceutical ... its US FDA approved and China CFDA certified ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
... South Korea, Feb. 25 Dong-A PharmTech Co., ... Pharma, has initiated,a 200 patient, phase 2 proof ... udenafil, a long acting phosphodiesterase type 5 inhibitor, ... European,study is designed to investigate the safety and ...
... Enterprise Intelligence Systems to Healthcare Market, ... #1841 --,Harris Corporation (NYSE: HRS ), ... joined forces with Cancer Treatment,Services International (CTSI) ... oncology. Harris will provide advanced imaging and ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment 2
(Date:8/20/2014)... August 20, 2014 Biocide Systems ... on Wrench Advisors as a consultant and partner ... large accounts. , As Wrench Advisors explains on ... help your organization plan and execute programs by ... distribution channels. Our experience developing joint venture partnerships ...
(Date:8/20/2014)... TX (PRWEB) August 20, 2014 The ... Surgery (ACPS), has expanded its presence throughout Houston to ... Mann Eye Institute and Laser Center building. ACPS plastic ... natural step forward for ACPS, which has risen to ... plastic surgery practices in the state since its establishment ...
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- White, straight women ... than minority, bisexual or lesbian women, a new study ... American women, aged 21 to 44, who took part ... of the National Survey of Family Growth study. ... women said they sought treatment for infertility. This ranged ...
(Date:8/20/2014)... receiving mental health services from the Veterans Health Administration ... among all areas studied. , The RAND Corporation study, ... a substance use disorder were less satisfied than other ... abuse problems also were less likely than others to ... decisions. , The findings, published in the journal ...
(Date:8/20/2014)... predict both breast cancer relapses and responses to ... The newly found marker could help doctors classify ... regimen that is more effective. The discovery was ... of Molecular and Cell Biology (IMCB), and the ... the National University of Singapore (NUS). , Despite ...
Breaking Medicine News(10 mins):Health News:Biocide Systems Announces Partnership with Wrench Advisors 2Health News:Aesthetic Center for Plastic Surgery Expands Its Reach in Texas 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2Health News:Survey finds veterans generally satisfied with mental health care 2Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2
... of winning a battle with cancer, as opposed to adults, ... years ago.// A recent report has explained that despite ... absolve them from the risks of long-term health problems in ... Childhood Cancer Survivor Study is a long-standing pioneer in the ...
... patients with severe psoriasis, appear to be at increased ... in the October 11 issue of JAMA.// ,Psoriasis ... percent to 3 percent of the adult population. It ... increased C-reactive protein levels, which have been linked to ...
... Kankova and colleagues from the Departments of Parasitology, Microbiology ... and GynCentrum, in the Czech Republic, women with dormant ... who are Toxoplasma negative. // ,Toxoplasma gondii ... with a universal occurrence of 20-80%. This study is ...
... for answers, but when it comes to cancer, physicians ... cancers. While certain tests can indicate the possibility of ... to monitor patients for cancer currently is not available ... University of Virginia School of Medicine are out to ...
... Parents with allergic symptoms like wheezing, asthma, hay ... to their infants too, according to a study by ... practice of avoiding skin testing for airborne allergens before ... in this high-risk group can be detected early and ...
... dengue death was reported in the capital, taking the toll ... city hospitals.// ,The total number of dengue cases in ... victim of the mosquito-borne viral disease was 25-year-old Farahan of ... Medical Science (AIIMS) here Friday and died in the early ...
Cached Medicine News:Health News:Childhood Cancer Survivors May Suffer Health Problems in Adulthood 2Health News:Psoriasis Associated With Increased Risk For Heart Attack 2Health News:Effect of parasitic infection on baby's sex 2Health News:Researchers Developing Office-Based Cancer Screening Test 2Health News:Allergy Sufferers Pass on Allergies to their Children 2Health News:Dengue Claims Yet Another Victim in Delhi 2
Manual Lensmeter....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
... 101 is well suited for measuring ... well as conventional spectacle lenses. It ... a full 90-degree inclination, which facilitates ... used in the vertical position. The ...
Medicine Products: